WWC1 and Mental deterioration: To advance clinical application and potentially identify individuals that could benefit from a KIBRA therapeutic, future studies should focus on evaluating KIBRA as a biomarker of synapse dysfunction and cognitive decline together with engineering a CT-KIBRA–based therapeutic that can be delivered across the blood-brain barrier into the brain.